Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Tolerability of ZOMACTON 10mg via ZomaJet Vision X
NCT00250250Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Oct 2005
- Primary completion
- Mar 2006
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of somatropin in Growth failure (FTT) and Turner syndrome (TS), sponsored by Ferring Pharmaceuticals. Primary endpoint: Local tolerability of ZOMACTON 10 mg administered by ZomaJet Vision X. Started Oct 2005; status: completed.
02
Drugs
somatropin
03
Conditions
Growth failure (FTT)Turner syndrome (TS)
Beyond the preview
Go deeper on NCT00250250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250250.